Arvinas, Pfizer Breast Cancer Drug Fails To Show Progression-Free Survival Benefit In Trial

Core Insights - Arvinas, Inc. and Pfizer Inc. announced topline results from the Phase 3 VERITAC-2 trial for vepdegestrant in advanced or metastatic breast cancer patients [1][2] - The trial focused on estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) patients who had disease progression after prior treatments [2] Trial Results - The trial met its primary endpoint in the estrogen receptor 1-mutant (ESR1m) population, showing a statistically significant improvement in progression-free survival (PFS) compared to fulvestrant [3] - The results surpassed the pre-specified target hazard ratio of 0.60 in the ESR1m population [4] - No statistical significance was found in PFS improvement in the intent-to-treat (ITT) population, and overall survival data was not mature at the time of analysis [4] Future Plans and Designations - The trial will continue to evaluate overall survival as a key secondary endpoint [5] - Vepdegestrant was generally well tolerated during the trial [5] - Detailed results will be presented at a medical meeting later this year, and the FDA granted Fast Track designation for vepdegestrant for monotherapy in eligible patients [5] Market Reaction - Following the trial results, ARVN stock experienced a decline of 52.4%, trading at $8.35 [6]